Jeremy Schubert
CEO
3H
3EO Health
3eohealth.com
Website unreachable since Oct 22, 2026
3EO Health utilizes patented 3TR amplification technology to deliver PCR-level sensitivity and specificity in respiratory diagnostics at a cost up to 70% lower than existing molecular tests. This preparation-free solution enables direct-to-test workflows, addressing the need for efficient and affordable diagnostic options in healthcare settings.
- Biotechnology
- Healthcare Technology
Updated 23 months ago
Funding
Raised to date
$13MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current respiratory diagnostic solutions lack a cost-effective option that combines the sensitivity and specificity of PCR-based molecular tests with the affordability and ease of use of antigen tests. Existing molecular tests are often too expensive and complex, while antigen tests suffer from suboptimal performance in detecting respiratory pathogens.
Solution
3EO Health offers a respiratory diagnostic solution leveraging its patented 3TR amplification technology to achieve PCR-level sensitivity and specificity at a significantly lower cost, up to 70% less than traditional molecular tests. The preparation-free technology enables a direct-to-test workflow, eliminating the need for time-consuming and technique-dependent sample preparation steps. This approach reduces the hidden costs associated with staff time, maintenance, quality control, and wastage. The compact design facilitates near-patient testing, making it suitable for point-of-care settings.
Target Audience
The primary target audience includes physicians, healthcare providers, and consumers seeking affordable and accurate respiratory diagnostic solutions for point-of-care testing and efficient disease management.
Features
- Patented 3TR amplification technology for enhanced sensitivity and specificity
- PCR-level performance with a limit of detection (LoD) of 733 copies per mL
- Preparation-free, direct-to-test workflow, eliminating sample preparation steps
- Compact "Cube" design for near-patient testing in various settings
- Cost-effective solution with a price point comparable to antigen tests
- Resilience to documented variants of respiratory pathogens